The effects of fentanyl, alfentanil and remifentanil on the cardiovascular responses during rigid bronchoscopy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31439885

Enrollment

Registered

2005-09-30

Start date

2003-09-25

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular: Circulatory System

Interventions

Patients undergoing rigid bronchoscopy will be randomised into the three drug groups. Measurement of muscle relaxation, arterial blood pressure and heart rate.

Eligibility

Inclusion criteria

Inclusion criteria: 60 adults

Exclusion criteria

Exclusion criteria: 1. Untreated systemic hypertension with SABP>160mmHg and /or DABP> 105mm Hg 2. Arythmias and heart conduction defects 3. Severe bronchial asthma

Design outcomes

Primary

Measure	Time frame
Changes in arterial blood pressures and heart rate.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026